Ascendis Pharma authorizes $400M share buyback
Ascendis Pharma has authorized a share buyback program worth $400 million. Separately, Seatrium announced a new buyback programme of up to 2% of issued shares, valued at S$200 million. Coverage highlights the scale of buybacks and the companies’ capital-return moves.
economy2 h ago
